Characteristics at initial diagnosis of 44 CNS-negative patients with acute lymphoblastic leukemia, 21 CNS-positive patients, and 21 patients subsequently relapsing with CNS involvement
| . | CNS negative (n = 44) (%) . | CNS positive (n = 21) (%) . | CNS relapse (n = 21) (%) . | P* . |
|---|---|---|---|---|
| Age (years) | ||||
| 1 to <10 | 28 (63.6) | 14 (66.7) | 14 (66.7) | |
| ≥10 | 16 (36.4) | 7 (36.3) | 7 (36.3) | 1.000 |
| Sex | ||||
| Male | 26 (59.1) | 12 (57.1) | 16 (76.2) | |
| Female | 18 (40.9) | 9 (42.9) | 5 (23.8) | .390 |
| Presenting white blood cell count/µL | ||||
| <10 000 | 7 (15.9) | 3 (14.3) | 6 (28.6) | |
| 10 000 to <50 000 | 20 (45.4) | 8 (38.1) | 5 (23.8) | |
| 50 000 to <100 000 | 9 (20.5) | 4 (19.0) | 4 (19.0) | |
| ≥100 000 | 8 (18.2) | 6 (28.6) | 6 (28.6) | .636 |
| Immunophenotype | ||||
| B-precursor | 44 (100.0) | 21 (100.0) | 18 (85.7) | |
| T-ALL | 0 | 0 | 3 (14.3) | .808 |
| BCR/ABL | ||||
| Negative | 44 (100.0) | 18 (85.6) | 19 (90.4) | .104 |
| Positive | 0 | 1 (4.8) | 2 (9.6) | |
| Not known | 0 | 2 (9.6) | 0 | |
| ETV6/RUNX1 | ||||
| Negative | 44 (100.0) | 16 (76.2) | 18 (85.7) | .01 |
| Positive | 0 | 4 (19.1) | 2 (9.5) | |
| Not known | 0 | 1 (4.7) | 1 (4.8) | |
| MLL/AF4 | ||||
| Positive | 0 | 0 | 0 | |
| Treatment group | ||||
| Standard risk | 18 (41.0) | 8 (38.1) | 2 (9.5) | |
| Intermediate risk | 9 (20.4) | 7 (33.3) | 14 (66.7) | |
| High risk | 17 (38.6) | 6 (28.6) | 5 (23.8) | .007 |
| . | CNS negative (n = 44) (%) . | CNS positive (n = 21) (%) . | CNS relapse (n = 21) (%) . | P* . |
|---|---|---|---|---|
| Age (years) | ||||
| 1 to <10 | 28 (63.6) | 14 (66.7) | 14 (66.7) | |
| ≥10 | 16 (36.4) | 7 (36.3) | 7 (36.3) | 1.000 |
| Sex | ||||
| Male | 26 (59.1) | 12 (57.1) | 16 (76.2) | |
| Female | 18 (40.9) | 9 (42.9) | 5 (23.8) | .390 |
| Presenting white blood cell count/µL | ||||
| <10 000 | 7 (15.9) | 3 (14.3) | 6 (28.6) | |
| 10 000 to <50 000 | 20 (45.4) | 8 (38.1) | 5 (23.8) | |
| 50 000 to <100 000 | 9 (20.5) | 4 (19.0) | 4 (19.0) | |
| ≥100 000 | 8 (18.2) | 6 (28.6) | 6 (28.6) | .636 |
| Immunophenotype | ||||
| B-precursor | 44 (100.0) | 21 (100.0) | 18 (85.7) | |
| T-ALL | 0 | 0 | 3 (14.3) | .808 |
| BCR/ABL | ||||
| Negative | 44 (100.0) | 18 (85.6) | 19 (90.4) | .104 |
| Positive | 0 | 1 (4.8) | 2 (9.6) | |
| Not known | 0 | 2 (9.6) | 0 | |
| ETV6/RUNX1 | ||||
| Negative | 44 (100.0) | 16 (76.2) | 18 (85.7) | .01 |
| Positive | 0 | 4 (19.1) | 2 (9.5) | |
| Not known | 0 | 1 (4.7) | 1 (4.8) | |
| MLL/AF4 | ||||
| Positive | 0 | 0 | 0 | |
| Treatment group | ||||
| Standard risk | 18 (41.0) | 8 (38.1) | 2 (9.5) | |
| Intermediate risk | 9 (20.4) | 7 (33.3) | 14 (66.7) | |
| High risk | 17 (38.6) | 6 (28.6) | 5 (23.8) | .007 |
χ2 or Fisher’s exact test.
ETV6, ets variant 6; RUNX1, runt-related transcription factor 1.